Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-117

With due respect....’placebo affect’ is irrelevant.

We’re talking about measurement of inflammation and muscle fiber damage....tangible, hard data.

Please DYOR on secondary end points of this study and....

The background / street cred of ANP’s scientific board.

Don’t worry about ‘tiny patient population’, DMD is a +$7B market.

But here is the blue sky....the wider CD49d market is MASSIVE.

If ATL1102 can reduce inflammation in DMD, where else can it be applied?

Interested how the guys at Platinum play this one....they know how to pick winners.